News & Events
Ethicon launches new surgical simulation tool, ‘Touch Surgery’, across EMEA
Ethicon*, part of Johnson & Johnson Medical Devices Companies (JJMD), has launched Touch Surgery for Europe, the Middle East & Africa (EMEA) at the 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Diseases (IFSO 2017). The 3D, app-based surgical simulation platform lets surgeons and medical students learn and master key surgical steps in bariatric surgery as well as another planned, 40 additional procedures.
The EMEA launch of Touch Surgery builds upon Ethicon’s existing professional education offering, emphasizing the company’s commitment to helping patients gain access to quality care. Earlier this year, Ethicon also partnered with Medscape to create a digital learning program for healthcare professionals to explore the role and make a case for bariatric surgery in the treatment of obesity and associated type 2 diabetes.
“At Ethicon, we want to improve the standards of care in bariatric surgery, accelerating our pace of innovation and aiding the training of more healthcare professionals” said Michael del Prado, Company Group Chairman for Ethicon. “We’ve made some great strides recently, and the availability of Touch Surgery in both the U.S. and EMEA, in conjunction with our Medscape partnership, are examples of the important steps we are taking towards developing a trusted education ecosystem that will ultimately help to improve patient outcomes.”
At Ethicon, we want to improve the standards of care in bariatric surgery, accelerating our pace of innovation and aiding the training of more healthcare professionals. We’ve made some great strides recently, and the availability of Touch Surgery in both the U.S. and EMEA, in conjunction with our Medscape partnership, are examples of the important steps we are taking towards developing a trusted education ecosystem that will ultimately help to improve patient outcomes.
Michael del Prado, Company Group Chairman for Ethicon
Touch Surgery is one of many Clinical Partnerships offered as part of JJMD’s CareAdvantage approach, providing a range of benefits, tailored to healthcare providers’ specific needs and priorities. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients. JJMD is working side-by-side with healthcare partners to develop research, real world evidence, and economic validation while delivering state-of-the-art education.
In a further demonstration of the company’s dedication to driving value-based healthcare, the CareAdvantage team will showcase its patient management tools — Care4Today Obesity (available in EMEA) and Health Partner for Weight Loss Surgery (available in U.S.) — for the first time at IFSO 2017. The app-based programs are designed to support patients with obesity and their healthcare professionals through the provision of comprehensive disease management across the patient pathway.
“We are focused on shaping the future of surgery in the fight against obesity and metabolic disease” said Silvia De Dominicis, Ethicon Franchise Vice President for EMEA. “Through the delivery of tools and programs to educate healthcare professionals, support patients throughout their treatment pathway and raise broad awareness of obesity, we are committed to helping patients gain access to effective treatment, including bariatric surgery. We believe it’s time to act, and this is exactly what we are doing.”
In Europe, it is now estimated that approximately 20 percent of the adult population is obese,i and this has significant economic implications too, with more than €33 billion annual health care costs being attributed to obesity.ii Ethicon is committed to leading the way in resolving the burden of obesity for both patients and healthcare systems around the world, by driving access and demonstrating the critical value of treatment.
The company will be showcasing current technologies, research and evidence, and access to care initiatives throughout IFSO 2017. Visit Booth #1 in the Fleming Exhibition Area, for more information.
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Family of Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing healthcare issues, and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Follow us on Twitter @Ethicon.
CareAdvantage is a data-driven, holistic approach in which Johnson & Johnson Medical Devices (JJMD) partners with hospitals and other healthcare providers to help deliver on the triple aim of enhancing patient experience, improving outcomes and reducing costs. CareAdvantage begins with a structured and in-depth assessment based on performance data and insights. Gathering this information and context is fundamental to the CareAdvantage approach, and helps ensure the solutions deliver value at every point along the care pathway.
About the JJMD Companies
The JJMD Companies' purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs, and research and development capabilities in surgical technology, orthopedics, cardiovascular, and specialty solutions with an offering directed at delivering clinical and economic value to healthcare systems worldwide.
+44 (0) 7917 534175
+44 (0) 20 7173 4098
* Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates.
ii World Health Organization Health Topics. http://www.euro.who.int/en/health-topics/noncommunicable- diseases/obesity/data-and-statistics [Accessed August 16, 2017].
iii Fry J, Finley W. The prevalence and costs of obesity in the EU. Proceedings of the Nutrition Society. 2005;64:359–362